Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
ALKS 3831
print preview
bookmark
share with colleague
General Information
Company
Alkermes plc
Description
Combination of ALKS 33, an opioid receptor modulator, and olanzapine, an antipsychotic monoaminergic receptor antagonist
Molecular Target
Opioid receptor (OPR)
Mechanism of Action
Latest Stage of Development
Phase I
Indication
Schizophrenia
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy